|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei J, Wu ND and Liu BR: Regional but
fatal: Intraperitoneal metastasis in gastric cancer. World J
Gastroenterol. 22:7478–7485. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jeon MY, Park JC, Hahn KY, Shin SK, Lee SK
and Lee YC: Long-term outcomes after noncurative endoscopic
resection of early gastric cancer: The optimal time for additional
endoscopic treatment. Gastrointest Endosc. Oct 12–2017.(Epub ahead
of print).
|
|
4
|
Peixoto A, Santos-Antunes J, Silva M and
Macedo G: Duodenal stump recurrence of gastric adenocarcinoma after
subtotal gastrectomy. Rev Esp Enferm Dig. 108:739–740.
2016.PubMed/NCBI
|
|
5
|
Yasumoto K, Koizumi K, Kawashima A, Saitoh
Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi
Y, et al: Role of the CXCL12/CXCR4 axis in peritoneal
carcinomatosis of gastric cancer. Cancer Res. 66:2181–2187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ajani JA: Evolving chemotherapy for
advanced gastric cancer. Oncologist. 10:49–58. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamangar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Charalampakis N, Elimova E, Shimodaira Y,
Shiozaki H, Wadhwa R and Ajani JA: Biologics in combination with
chemotherapy for gastric cancer: Is this the answer? Expert Opin
Pharmacother. 16:955–960. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cuajungco MP, Podevin W, Valluri VK, Bui
Q, Nguyen VH and Taylor K: Abnormal accumulation of human
transmembrane (TMEM)-176A and 176B proteins is associated with
cancer pathology. Acta Histochem. 114:705–712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wrzesiński T, Szelag M, Cieślikowski WA,
Ida A, Giles R, Zodro E, Szumska J, Poźniak J, Kwias Z, Bluyssen
HA, et al: Expression of pre-selected TMEMs with predicted ER
localization as potential classifiers of ccRCC tumors. BMC Cancer.
15:5182015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu R, Hu F, Xie X, Wang L, Li G, Qiao T,
Wang M and Xiao H: TMEM45B, up-regulated in human lung cancer,
enhances tumorigenicity of lung cancer cells. Tumour Biol.
37:12181–12191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu D, Qu L, Hu J, Li G, Lv P, Ma D, Guo M
and Chen Y: Transmembrane protein 106A is silenced by promoter
region hypermethylation and suppresses gastric cancer growth by
inducing apoptosis. J Cell Mol Med. 18:1655–1666. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hisa I, Inoue Y, Hendy GN, Canaff L,
Kitazawa R, Kitazawa S, Komori T, Sugimoto T, Seino S and Kaji H:
Parathyroid hormone-responsive Smad3-related factor, Tmem119,
promotes osteoblast differentiation and interacts with the bone
morphogenetic protein-Runx2 pathway. J Biol Chem. 286:9787–9796.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang ZH, Peng J, Yang HL, Fu XL, Wang JZ,
Liu L, Jiang JN, Tan YF and Ge ZJ: Upregulation and biological
function of transmembrane protein 119 in osteosarcoma. Exp Mol Med.
49:3292017. View Article : Google Scholar
|
|
15
|
Satoh J, Kino Y, Asahina N, Takitani M,
Miyoshi J, Ishida T and Saito Y: TMEM119 marks a subset of
microglia in the human brain. Neuropathology. 36:39–49. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu F, Cao QH, Lu DJ, Luo B, Lu XF, Luo RC
and Wang XG: TMEM16A overexpression contributes to tumor invasion
and poor prognosis of human gastric cancer through TGF-β signaling.
Oncotarget. 6:11585–11599. 2015.PubMed/NCBI
|
|
17
|
Kim KY, Cho HJ, Yu SN, Kim SH, Yu HS, Park
YM, Mirkheshti N, Kim SY, Song CS, Chatterjee B, et al: Interplay
of reactive oxygen species, intracellular Ca2+ and mitochondrial
homeostasis in the apoptosis of prostate cancer cells by
deoxypodophyllotoxin. J Cell Biochem. 114:1124–1134. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sharifi S, Barar J, Hejazi MS and Samadi
N: Doxorubicin Changes Bax /Bcl-xL Ratio, Caspase-8 and 9 in breast
cancer cells. Adv Pharm Bull. 5:351–359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song Y, Li X, Li Y, Li N, Shi X, Ding H,
Zhang Y, Li X, Liu G and Wang Z: Non-esterified fatty acids
activate the ROS-p38-p53/Nrf2 signaling pathway to induce bovine
hepatocyte apoptosis in vitro. Apoptosis. 19:984–997. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao J, Gao J, Qian L, Wang X, Wu M, Zhang
Y, Ye H, Zhu S, Yu Y and Han W: Activation of p38-MAPK by
CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis
initiated by 5-fluorouracil. Cancer Biol Ther. 15:982–991. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Akl H, Vervloessem T, Kiviluoto S,
Bittremieux M, Parys JB, De Smedt H and Bultynck G: A dual role for
the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus
endoplasmic reticulum. Biochim Biophys Acta. 1843:2240–2252. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
